SCHEMBL2909697

SCHEMBL2909697

COc1cc(O[Si](C)(C)C(C)(C)C)cc(OC)c1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.32
CA1 P00915 4/20 0.32
CA9 Q16790 4/20 0.32
SNCA P37840 1/20 0.31
PREP P48147 1/20 0.30
CSF1R P07333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022429 0.82 CA12 (0.33) CA12CA1CA9PREP
SCHEMBL15475652 0.82 CA1 (0.38) CA12CA1CA9SNCAPREP
SCHEMBL5899744 0.81 CA1 (0.38) CA12CA1CA9SNCACSF1R
SCHEMBL325339 0.81 CA12 (0.33) CA12CA1CA9
SCHEMBL9986782 0.78 FFAR1 (0.37) CA12CA1CA9SNCA
SCHEMBL21835765 0.76 CA12 (0.30) CA12CA1CA9
SCHEMBL23123508 0.75 EGFR (0.38)
SCHEMBL18736534 0.73 FFAR1 (0.37) CA12CA1CA9SNCA
SCHEMBL26334789 0.73 FFAR1 (0.34) CA12CA1CA9SNCAPREP
SCHEMBL13139651 0.73 MAPT (0.45) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140413-A1 WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES CISBIO BIOASSAYS (FR) 2020-05-07 US disclosed
US-10597409-B2 Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes CISBIO BIOASSAYS (FR) 2020-03-24 US disclosed
EP-3386974-B1 WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES CISBIO BIOASSAYS (FR) 2020-02-05 EP disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140413-A1 WATER-SOLUBLE TRIMETHOXYPHENYLPYRIDINE-TYPE COMPLEXING AGENTS, AND CORRESPONDING LANTHANIDE COMPLEXES RCC1, LASP1, POT1 CA12 841/4885CA1 315/4885CA9 379/4885
US-10597409-B2 Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes GSTA1, CLIC1, SLC40A1 CA12 1289/4885CA1 856/4885CA9 1467/4885
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 CA12 4685/4885CA1 4452/4885CA9 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.